Coronary/Structural Heart

Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 13th, 2020 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the third annual Cytokinetics Communications Fellowship Grant program. The Communications Fellowship program provides a total of $100,000 […]

World’s largest study of cardiovascular disease in type 2 diabetes shows need for improved knowledge and disease management

Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants […]

OrbusNeich® Announces China Approval for COMBO® Coronary Stent

HONG KONG, Sept. 23, 2020 /PRNewswire/ — OrbusNeich Medical Co. Ltd. has announced that the National Medical Products Administration (NMPA) has granted market approval for the COMBO BIO-ENGINEERED SIROLIMUS ELUTING STENT in China. It is the first dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the […]

Medtronic Receives FDA “Breakthrough Device Designation” for TYRX Driveline Wrap Device

DUBLIN, Sept. 22, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the TYRX™ Absorbable Antibacterial Driveline Wrap, which is intended to securely hold a percutaneous driveline in patients receiving a ventricular assist device (VAD). […]

SVMHS Among Nation’s Top Performing Hospitals for Treatment of Heart Attack Patients

SALINAS, Calif., Sept. 23, 2020 /PRNewswire/ — During unprecedented challenges in healthcare, Salinas Valley Memorial Healthcare System (SVMHS) is providing medical leadership during COVID-19 and earning awards for exceptional patient care in the area of heart treatment. SVMHS is one of only 60 hospitals nationwide to receive the American College of Cardiology’s NCDR […]

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271

Company Advances Second Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered […]

MedHub Receives CE Mark Approval for its AutoCathFFR Software

TEL AVIV, Israel, Sept. 22, 2020 /PRNewswire/ — MedHub, a med-tech company that is leveraging AI to help interventional cardiologists make better decisions, announced today that its AutoCathFFR system has been certified to bear the CE Mark, signifying compliance with the European Union’s health and environmental safety regulations. “Following our recent AMAR regulatory approval, the […]

Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation

– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option ABBOTT […]

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 […]

Compelling New Research Links Increased Omega-3 Intake to Improved Cardiovascular Outcomes

Study published in Mayo Clinic Proceedings supports multiple cardiovascular risk reductions SALT LAKE CITY, Sept. 17, 2020 /PRNewswire/ — A new study, the most comprehensive analysis of the role of omega-3 dosage on cardiovascular prevention to date, provides compelling evidence for consuming more EPA and DHA (eicosapentaenoic acid and docosahexaenoic acid, respectively) […]